Cardiff Oncology (CRDF) Change in Receivables (2011 - 2025)

Cardiff Oncology has reported Change in Receivables for 15 years, with the latest figure at -$72000.0 in Q4 2025.

• Quarterly Change in Receivables fell 146.75% year-over-year to -$72000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$591000.0 (down 222.11% YoY) and the FY2025 annual result came in at -$591000.0, down 222.11% from the prior year.
• Change in Receivables climbed to -$72000.0 in Q4 2025 per CRDF's latest filing, from -$272000.0 in the prior quarter.
• Over five years, Change in Receivables peaked at $167000.0 in Q3 2024 and troughed at -$515000.0 in Q2 2023.
• A 5-year average of -$6950.0 and a median of $76500.0 in 2021 frame the typical range for Change in Receivables.
• The sharpest annual moves came in 2021 and 2023: Change in Receivables surged 2133.33% in 2021, then sank 595.19% in 2023.
• Over 5 years, Change in Receivables stood at $141000.0 in 2021, then decreased by 14.18% to $121000.0 in 2022, then slipped by 25.62% to $90000.0 in 2023, then soared by 71.11% to $154000.0 in 2024, then sank by 146.75% to -$72000.0 in 2025.
• According to Business Quant data, Change in Receivables over the past three periods registered -$72000.0, -$272000.0, and $121000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.